The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
The PHOENIX clinical trial investigated the addition of ibrutinib to R-CHOP in a pre-selected subpopulation of patients with non-GCB and ABC diffuse large B-cell lymphoma (NCT01855750). Although this trial did not meet the primary endpoint of event-free survival, upon further analysis a link was found between age and response to treatment. Anas Younes, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the details of the sub-analysis conducted, which were presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
